Merck KEYTRUDA gets USFDA priority review for its Second Application Medical Dialogues Bureau9 April 2020 3:30 AM GMTKenilworth: Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has accepted and...
Merck gets Japanese nod for TEPMETKO(tepotinib) for non-small cell lung cancer Medical Dialogues Bureau28 March 2020 6:15 AM GMTTEPMETKO is the first regulatory approval globally for an oral MET inhibitor indicated for the treatment of advanced NSCLC harboring MET gene...
Merck Announces positive results for Gefapixant Phase 3 Trial to treat Chronic Cough Medical Dialogues Bureau21 March 2020 4:45 AM GMTKenilworth: Merck, known as MSD outside the United States and Canada, has announced top-line efficacy results from two ongoing pivotal Phase 3...
Merck, AMCM collaborates for 3D Printing of Tablets Medical Dialogues Bureau1 March 2020 5:00 AM GMT3D printing allows for API (active pharmaceutical development) formulation to be scalable while avoiding costly reformulations throughout the entire...
Merck Ebola vaccine Ervebo to be available at lowest access price for poor nations Medical Dialogues Bureau24 Dec 2019 3:30 AM GMTThe vaccine, Ervebo, was approved by the U.S. Food and Drug Administration on Thursday, a month after Europe gave its nod to the vaccine, a move that...
Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial Medical Dialogues Bureau3 Nov 2019 3:30 AM GMTBristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to...
Merck loses bid to revive over Rs 18 crore patent verdict against Gilead Farhat Nasim31 Oct 2019 9:57 AM GMTIn 2016, a jury returned a verdict that Gilead Science's hepatitis C drugs Sovaldi and Harvoni infringed the patent, which Merck acquired when it...
Novo Nordisk wins USFDA nod for oral diabetes drug Rybelsus Medical Dialogues Bureau23 Sep 2019 8:46 AM GMTNovo Nordisk did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with...
Sanofi revival depends on outsider with nose for big drugs: Report Medical Dialogues Bureau3 Sep 2019 3:28 AM GMTDefining Sanofi's ambitions in the cutting-edge field of gene therapies and figuring out whether to hold on to consumer health brands are among other...
GSK Belantamab Mafodotin shows to help blood cancer patients Medical Dialogues Bureau26 Aug 2019 3:45 AM GMTTwo doses of Belantamab Mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the...
Canada enacts drug price crackdown, in blow to pharmaceutical industry Medical Dialogues Bureau11 Aug 2019 3:30 AM GMTThe changes are the biggest reform to Canada's drug price regime since 1987 and could eventually cut the earnings of drugmakers in the United States,...
Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel Medical Dialogues Bureau28 July 2019 3:47 AM GMTSales of Eliquis, which Bristol-Myers shares with Pfizer Inc (PFE.N), rose 24% to $2.04 billion, while Orencia sales rose 9% to $778 million, both...
